Immunoscintigraphy With 99mTc-Nimotuzumab for Planning Immunotherapy in Patients With Bone Metastases Due to Prostate Cancer

Quián, Yamilé Peña; Crombet, Tania; Batista, Juan F.; Prats, Anaís; Perera, Alejandro

doi:10.1097/rlu.0000000000001011

Cited by 5 publications

(4 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…6 Previous studies have demonstrated the anti-cancer effects of nimotuzumab in various types of cancers, including advanced head and neck cancer, 7 nasopharyngeal carcinoma, 8 esophageal squamous cell cancer, 9 as well as PCa. 10 Furthermore, in combination with oxidized tea polyphenols, nimotuzumab has shown enhanced inhibition of EGFR and tumor growth in non-small cell lung cancer cells and tumor-bearing mice. 11 Additionally, Hu et al revealed that nimotuzumab can markedly suppress malignant behaviors in PCa cell lines, such as epithelial-mesenchymal transition (EMT), invasion, migration, and proliferation.…”

Section: Introductionmentioning

confidence: 99%

“…Its mechanism of action involves competing with other specific ligands to target epidermal growth factor receptor (EGFR, effectively suppressing cancer development 6 . Previous studies have demonstrated the anti‐cancer effects of nimotuzumab in various types of cancers, including advanced head and neck cancer, 7 nasopharyngeal carcinoma, 8 esophageal squamous cell cancer, 9 as well as PCa 10 . Furthermore, in combination with oxidized tea polyphenols, nimotuzumab has shown enhanced inhibition of EGFR and tumor growth in non‐small cell lung cancer cells and tumor‐bearing mice 11 .…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

miR‐199a/214 cluster enhances prostate cancer sensitiveness to nimotuzumab via targeting TBL1XR1

Hu,

Zhou,

et al. 2023

The Kaohsiung J of Med Scie

View full text Add to dashboard Cite

Prostate cancer (PCa) is a significant health concern affecting men worldwide. Previous studies have shown that nimotuzumab, a drug targeting the epidermal growth factor receptor (EGFR), can effectively inhibit cancer progression. Here, we aimed to explore the role of miR‐199a/214 cluster in mediating the inhibitory effect of nimotuzumab on the development of PCa. In this study, we conducted an MTT assay to assess cell proliferation and utilized flow cytometry to evaluate cell apoptosis and cell cycle arrest. To investigate the molecular mechanisms underlying the effects of nimotuzumab on prostate cancer development, we focused on the miR‐199a‐5p and miR‐214‐3p miRNA clusters. The TargetScan Human database was used to predict the binding sites between miR‐199a‐5p or miR‐214‐3p and the 3'‐UTR of the transducin (β)‐like 1 X‐linked receptor 1 (TBL1XR1) mRNA. To confirm the direct interaction and binding between miR‐199a‐5p or miR‐214‐3p and the 3'‐UTR of TBL1XR1 mRNA, we performed luciferase reporter assays. Our findings demonstrated that nimotuzumab exerted a significant dosage‐dependent suppression of PCa cell proliferation and facilitated PCa cell apoptosis and cell cycle arrest. Concurrently, nimotuzumab obviously impeded the activity of Wnt/β‐catenin and EGFR signaling pathways in PCa cells. We also observed downregulation of miR‐199a‐5p and miR‐214‐3p in PCa cells. Overexpression of miR‐199a/214 cluster inhibited PCa cell viability and enhanced cell apoptosis. Furthermore, we found that miR‐199a/214 cluster augmented the inhibitory effect of nimotuzumab on PCa cell proliferation and promoted its ability to induce apoptosis and cell cycle arrest. This effect was reversed upon TBL1XR1 overexpression, indicating that TBL1XR1 is involved in the regulatory pathway of miR‐199a/214 and nimotuzumab in PCa cells. We further revealed that TBL1XR1 was overexpressed in PCa and was identified as a downstream target of the miR‐199a/214 cluster. In nimotuzumab‐treated PCa cells, the overexpression of miR‐199a/214 markedly inhibited Wnt/β‐catenin and EGFR signaling, and this effect was also rescued by TBL1XR1 overexpression. In summary, our data indicated that miR‐199a/214 cluster play a crucial role in enhancing the inhibitory effect of nimotuzumab on PCa development by downregulating TBL1XR1 and modulating Wnt/β‐catenin and EGFR signaling pathways. These findings offer a novel therapeutic approach for the treatment of prostate cancer.

show abstract

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

miR‐199a/214 cluster enhances prostate cancer sensitiveness to nimotuzumab via targeting TBL1XR1

Hu,

Zhou,

et al. 2023

The Kaohsiung J of Med Scie

View full text Add to dashboard Cite

show abstract

“…A recent case report showed that nimotuzumab reduced prostate‐specific antigen (PSA) level in a patient with both PC and colon cancer . Another study on two PC patients presenting bone metastasis reported metastasis‐inhibitory effect of nimotuzumab . Yet few studies have comprehensively examined the therapeutic efficacy of nimotuzumab in PC.…”

Section: Introductionmentioning

confidence: 99%

Nimotuzumab inhibits epithelial–mesenchymal transition in prostate cancer by targeting the Akt/YB‐1/AR axis

Duan

Zhou

et al. 2019

IUBMB Life

View full text Add to dashboard Cite

Nimotuzumab is a humanized anti‐EGF monoclonal antibody that has been approved for treating different cancers. However, few studies have examined its therapeutic potential in prostate cancer (PC), a most common and highly aggressive malignancy among male population. We used both LNCaP, and PC3 and PC3‐AR (androgen receptor) cells as the model system and assessed the effects of nimotuzumab on epithelial–mesenchymal transition (EMT) in vitro and in vivo. The EMT makers were detected by immunohistochemistry, qRT‐PCR and Western blot. MTT, wound healing assay, and transwell assay were used to measure cell viability, migration, and invasion, respectively. For mechanistic understanding, we evaluated the significance of Akt/Y‐box binding protein‐1 (YB‐1)/AR axis in nimotuzumab‐induced EMT by overexpressing AR, activating Akt using SC79, and/or downregulating YB‐1 using siRNA. Nimotuzumab suppressed the xenograft growth from both LNCaP and PC3 cells in vivo, which was associated with reduced EMT. Consistently, nimotuzumab inhibited proliferation, cell‐cycle progression, EMT, and migration/invasion, but stimulated apoptosis of both LNCaP and PC3‐AR cells in vitro. On the molecular level, nimotuzumab inactivated Akt and YB‐1 and reduced the expression of AR. Boosting AR expression in LNCaP and PC3‐AR cells antagonized the action of nimotuzumab, at least partially restored EMT, and enhanced the migration/invasion. We also found that Akt was essential for controlling YB‐1 activation, and both critical for regulating the levels of AR and EMT‐related biomarkers. In this study, we presented our novel findings that by targeting the Akt/YB‐1/AR axis, nimotuzumab significantly inhibited EMT of PC cells. Considering that EMT is a critical mechanism contributing to the metastatic spread of cancer cells, nimotuzumab may become a promising therapy for alleviating the malignant progression of PC. © 2019 IUBMB Life, 1–14, 2019

show abstract

“…Nimotuzumab (hR3) is a humanized IgG1 monoclonal antibody directed against epidermal growth factor receptor (EGFr) [1][2][3][4]. It has potent anti-proliferative, antiangiogenic, and pro-apoptotic effects in vitro and in vivo.…”

mentioning

confidence: 99%

Immunoscintigraphy with 99mTc-14F7 and 99mTc-Nimotuzumab in patients with non-small cell lung cancer

Peña¹,

Crombet²,

A.Vergara³

et al. 2018

Trends Cancer Res Chemother

Self Cite

View full text Add to dashboard Cite

The immunoscintigraphy is a non-invasive technique with high specificity. The technique provides information on the location of the tumor and its metastases, detects specific biomarkers on the cell surface of tumors, characterizing it by establishing its biology and phenotype. It also evaluates the response to the treatment that is applied, and allows performing a personalized targeted therapy.The authors show the imagines of two patients with non-small cell lung cancer after administration of the 99m Tc-14F7 and 99m Tc-Nimotuzumab. The tumors showed high expression of specific antigens.

show abstract

Immunoscintigraphy With 99mTc-Nimotuzumab for Planning Immunotherapy in Patients With Bone Metastases Due to Prostate Cancer

Cited by 5 publications

References 7 publications

miR‐199a/214 cluster enhances prostate cancer sensitiveness to nimotuzumab via targeting TBL1XR1

miR‐199a/214 cluster enhances prostate cancer sensitiveness to nimotuzumab via targeting TBL1XR1

Nimotuzumab inhibits epithelial–mesenchymal transition in prostate cancer by targeting the Akt/YB‐1/AR axis

Immunoscintigraphy with 99mTc-14F7 and 99mTc-Nimotuzumab in patients with non-small cell lung cancer

Contact Info

Product

Resources

About